Rigel Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RIGL research report →
Companywww.rigel.com
Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
- CEO
- Raul R. Rodriguez
- IPO
- 2000
- Employees
- 162
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $533.23M
- P/E
- 1.46
- P/S
- 1.78
- P/B
- 1.33
- EV/EBITDA
- 4.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.39%
- Op Margin
- 41.56%
- Net Margin
- 121.51%
- ROE
- 147.03%
- ROIC
- 27.96%
Growth & Income
- Revenue
- $294.28M · 64.15%
- Net Income
- $367.02M · 1999.08%
- EPS
- $20.40 · 1960.61%
- Op Income
- $125.47M
- FCF YoY
- 143.46%
Performance & Tape
- 52W High
- $52.24
- 52W Low
- $18.14
- 50D MA
- $28.55
- 200D MA
- $34.65
- Beta
- 1.20
- Avg Volume
- 401.87K
Get TickerSpark's AI analysis on RIGL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Wasman Jane | other | 5,750 |
| May 15, 26 | MOOS WALTER H | other | 5,750 |
| May 15, 26 | MILLER MICHAEL PATRICK | other | 5,750 |
| May 15, 26 | LAPOINTE ANTHONY GREGG | other | 5,750 |
| May 15, 26 | HANNAH ALISON L. | other | 5,750 |
| May 15, 26 | Frohlich Mark W | other | 5,750 |
| May 15, 26 | Ali-Jackson Kamil | other | 5,750 |
| Feb 20, 26 | MOOS WALTER H | other | 4,000 |
| Feb 20, 26 | MOOS WALTER H | sell | 4,000 |
| Feb 20, 26 | MOOS WALTER H | other | 4,000 |
Our RIGL Coverage
We haven't published any research on RIGL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RIGL Report →